News Releases

News and information from The Leukemia & Lymphoma Society

FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder

Rye Brook, N.Y. (January 19, 2021) – On January 15, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with newly diagnosed light chain (AL) amyloidosis, a rare and serious blood cell disorder that may occur by itself or with myeloma. Daratumumab is used in combination with chemotherapy agents bortezomib (Velcade®) and cyclophosphamide (C...

The Leukemia & Lymphoma Society Applauds Bipartisan Agreement to Stop Surprise Medical Bills

Rye Brook, NY (December 21, 2020) - The Leukemia & Lymphoma Society issues the following statement in response to Congress including policies designed to protect patients from surprise medical bills in the stimulus bill scheduled for a vote Monday, Dec. 21, 2020: LLS applauds Congress for reaching a bipartisan agreement that will, after years of work, hold patients harmless from surprise medical bills.  ...

FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOMA

Rye Brook, N.Y. (December 18, 2020) – The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one prior type of treatment. Selinexor is used in combination with the chemotherapy drug bortezomib (Velcade®) and the corticosteroid dexamethasone in these patients. LLS supported development of selinexor with over $4 million i...

The Leukemia & Lymphoma Society Statement on COVID-19 Vaccine Distribution

At The Leukemia & Lymphoma Society (LLS), we hear from blood cancer patients and caregivers each day about the profound effects of the COVID-19 pandemic on their cancer care, treatment, and daily lives. As a patient-focused leader in the scientific and medical community, we are encouraged by the U.S. Food & Drug Administration (FDA) decision to grant emergency use authorization (EUA) to the first COVID-19 vac...

Collaboration Driving Progress: LLS Forms Alliances with Leading Cancer Institutions and Foundations to Co-Fund nearly $17 million in New Research Grants

Rye Brook, NY (December 14, 2020) – As the world confronts a viral pandemic not seen in the past 100 years, the reverberations are being felt across every sector, from healthcare to the economy, education, business and science, including the blood cancer community. Blood cancers don’t stop for the Covid-19 virus and the urgent need for collaboration to address these challenges has never been starker. In respon...

LLS Statement on Oral Arguments in California v. Texas

Rye Brook, NY (November 9, 2020) – This week, the Supreme Court of the United States hears oral arguments in California v. Texas, the case challenging the Affordable Care Act. The following is a statement from The Leukemia & Lymphoma Society’s Chief Medical Officer Gwen Nichols, M.D.: "For more than a decade, cancer patients have relied on the vital protections the Affordable Care Ac...

The Hairy Cell Leukemia Foundation and The Leukemia & Lymphoma Society Join Forces to Find New Therapies for Patients with this Rare Blood Cancer

New York, NY and Rye Brook, NY (November 2, 2020) - The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) announced today they are teaming up to support a research grants program of up to $10 million over five years, to build a more comprehensive understanding of hairy cell leukemia (HCL), develop better therapies and optimize outcomes for patients with HCL. The two organizations ...

Study in Nature Medicine Shows Superior Outcomes for Patients in LLS's Paradigm-Shifting Beat AML Clinical Trial

Rye Brook, NY (Monday, October 26, 2020) - Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal. The Beat AML trial achieved its prim...

Pages

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.